Growth I. L.P. M33 Sells 673,676 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Growth I. L.P. M33 sold 673,676 shares of the business’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $3.05, for a total value of $2,054,711.80. Following the sale, the director now owns 13,950,557 shares in the company, valued at approximately $42,549,198.85. This trade represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Oncology Institute Price Performance

Oncology Institute stock opened at $2.66 on Wednesday. The stock’s 50 day moving average is $2.56 and its 200 day moving average is $1.30. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The firm has a market cap of $237.36 million, a P/E ratio of -3.41 and a beta of 0.13. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $3.50.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. The company had revenue of $104.41 million during the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds and other institutional investors have recently made changes to their positions in TOI. Josh Arnold Investment Consultant LLC acquired a new position in shares of Oncology Institute in the first quarter worth approximately $2,267,000. FreeGulliver LLC lifted its stake in shares of Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after acquiring an additional 412,578 shares during the period. Tiff Advisory Services LLC lifted its stake in Oncology Institute by 13.2% in the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock valued at $921,000 after buying an additional 346,256 shares during the period. Virtu Financial LLC acquired a new position in Oncology Institute in the fourth quarter valued at approximately $41,000. Finally, Goldman Sachs Group Inc. acquired a new position in Oncology Institute in the first quarter valued at approximately $131,000. 36.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, BTIG Research began coverage on Oncology Institute in a report on Thursday, May 15th. They set a “buy” rating and a $7.00 price target on the stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.